HOME >> BIOLOGY >> NEWS
Long-term ulcerative colitis study shows Remicade responders maintained improvement

WASHINGTON, DC, May 23, 2007 Findings presented today at Digestive Disease Week 2007 (DDW), from long-term extensions of the ACT trials (Active Ulcerative Colitis 1 & 2) show that subjects with moderately to severely active ulcerative colitis (UC) who had responded to REMICADE (infliximab) in the blinded phase of the trials maintained improvement in their clinical symptoms for up to two years.

The ACT extension trials were conducted in both the United States and Europe, under co-principle investigators William Sandborn, M.D. of the Mayo Clinic and Walter Reinisch, M.D., of the University Hospital Vienna, Austria. The data show that for patients who completed follow-up through week 56 of the extension trials, 92 percent reported mild or no disease activity, as measured by the Physician's Global Assessment (PGA). For patients followed through week 104, 97 percent reported mild or no disease activity.

At week 0 of the ACT extension trials, 76 percent of 229 responder patients enrolled had mild or no disease activity, as indicated by a PGA score of 0 or 1, and 41 percent had no disease activity (PGA score of 0). At week 56, 92 percent of those patients remaining in the extension trials (n=181) had mild or no disease activity, and 61 percent had no disease activity. At week 104, 97 percent of those patients remaining in the extension trials (n=97) had mild or no disease activity, and 75 percent had no disease activity.

"The data demonstrate the sustained efficacy of REMICADE for many patients with UC," said co-principle investigator Walter Reinisch, M.D., of the University Hospital Vienna, Austria. "Because UC is a chronic condition, many patients live with cycles of recurring flares. This can greatly hinder a person's social and professional life. The availability of therapies that quickly reduce symptoms and maintain response and remission long term is a significant benefit to patients."

Separate data also presented at DDW
'"/>

Contact: Melissa Katz
mkatz2@cntus.jnj.com
215-325-6875
Centocor, Inc.
23-May-2007


Page: 1 2 3

Related biology news :

1. Long-term marijuana smoking leads to respiratory complaints
2. Long-term cancer risk follows stem cell transplant recipients
3. Long-term ocean data confirm fishing puts species in double jeopardy
4. Long-term lead exposure linked to cognitive decline in older adults
5. Long-term changes in experience cause neurons to sprout new long-lasting connections
6. Long-term study shows brain function not impaired by tight diabetes control and hypoglycemia
7. Long-term ecological research should include studies on how social science interacts with ecosystems
8. Long-term memory controlled by molecular pathway at synapses
9. Scientists find gene target that may protect against Crohns disease and ulcerative colitis
10. Data show treatment with Remicade reduced hospitalizations for ulcerative colitis patients by half
11. Data in New England Journal of Medicine show benefits of REMICADE in ulcerative colitis patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2019)... ... August 15, 2019 , ... Make ... staff of routine tasks. That was the message at the world's largest gathering ... Information. The American Association for Clinical Chemistry (AACC) Annual Scientific Meeting was held ...
(Date:8/14/2019)... ... August 14, 2019 , ... Join Jonathan Riek, PhD, VP, ... on Tuesday, September 10, 2019 at 1pm EDT to learn about two common imaging ... , NAFLD is the most common diffuse liver disease, with a worldwide prevalence ...
(Date:8/14/2019)... ... August 13, 2019 , ... Join Anguraj Sadanandam, PhD, Team ... Cancer Research (ICR) in a live webinar on Wednesday, September 4, ... and companion diagnostic development including machine learning approaches in different gastrointestinal cancers and ...
Breaking Biology News(10 mins):
(Date:7/9/2019)... ... July 08, 2019 , ... Balluff has ... was recognized as the 2019 Innovative Product of the Year which highlights cutting-edge ... were during Sensors Expo & Conference 2019, held this week in ...
(Date:6/26/2019)... ... June 26, 2019 , ... Alice Branton today released research results from preclinical ... Magnesium Gluconate, which can prove to be beneficial for treating Hypomagnesemia. , The preclinical ... change in crystallite size , Over 142% increase in particle size , ...
(Date:6/18/2019)... (PRWEB) , ... June 18, 2019 , ... Personalized ... Investigational New Drug (IND) application to the FDA for use of a person’s own ... as a treatment of osteoarthritis in the knee. This IND is the first ...
(Date:6/11/2019)... , ... June 10, 2019 , ... ... its distribution network with the appointment of Biofeedback Tech Ltd as ... systems are an essential part of many therapeutic treatments and clinical assessment protocols ...
Breaking Biology Technology:
Cached News: